BARCLAYS HAS DOWNGRADED NOVO NORDISK’S STOCK RATING FROM “Overweight“To”Equalweight“Following Mounting Concerns Over The Company’s Ability to Sustain ITS Dominance in the Rapidly Evolving Obesity Drug Sector.
The Move Comes On The Heels of Novo Nordisk’s Sharp Downward Revice of ITS 2025 Sales and Profit Outlooks, Which Triggered A Dramatic $ 70Billion Sell-Off in Market Value and A Drop of More than 20% in Share Price.
The Downgrade is underpinned by persistent, Company-Specific Headwinds. Chief Among Them is the prolonged Impact of composted glyp-1 production-Unbrand Alternatives That has significantly Eroded Market Share for Semaglutide, Novo’s Flagship Treatment Treatment Ingredient in Its Obesity Therapies.
You composeted verses have lingerered longer than anticipated in the us market, undermining Both pricing power and patient retention.
BARCLAYS ALSO CITED INTREGUYING COMPETITION, SPECIALLY FROM ELI LILY’S ORFORGLIPRON AND THE POTENTIAL ARRIVAL OF RESTITRUTIDE, BOY OF WHICH HAVE SHOWN “STELLAR” EFFICACY DATA AND ARE EXPECTED TO FURTER CROWD THE OBESITY TREATMENT.
Additionionally, Challenges in Novo Nordisk’s Late-Stage Drug Pipeline, Including Slow Advances and Regulatory Hurdles, Have Added to Investor UNEASE.
